Detalhe da pesquisa
1.
Pharmacokinetics and safety of LEAD-452, an EGFR-specific 4-1BB-agonistic trimerbody in non-human primates.
Toxicol Appl Pharmacol
; 487: 116961, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38740095
2.
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.
Oncoimmunology
; 12(1): 2205336, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37114242
3.
Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.
iScience
; 25(9): 104958, 2022 Sep 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36072551
4.
Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.
Cancer Immunol Res
; 10(4): 498-511, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35362043
5.
An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.
Clin Cancer Res
; 27(11): 3167-3177, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33785484
6.
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.
Nat Commun
; 9(1): 4809, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30442944